Abstract
The expression of vascular endothelial growth factor (VEGF) is elevated in diabetic macular edema (DME). Ranibizumab binds to and inhibits multiple VEGF variants. We investigated the safety and efficacy of ranibizumab in DME involving the foveal center.
| Originalsprog | Engelsk |
|---|---|
| Tidsskrift | Diabetes Care |
| Vol/bind | 33 |
| Udgave nummer | 11 |
| Sider (fra-til) | 2399-405 |
| Antal sider | 7 |
| ISSN | 0149-5992 |
| DOI | |
| Status | Udgivet - 1 nov. 2010 |
Fingeraftryk
Dyk ned i forskningsemnerne om 'Safety and efficacy of ranibizumab in diabetic macular edema (RESOLVE Study): a 12-month, randomized, controlled, double-masked, multicenter phase II study'. Sammen danner de et unikt fingeraftryk.Citationsformater
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS